Navigation Links
Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
Date:2/27/2008

TAMPA, Fla., Feb. 27 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced that its New Drug Application (NDA) for Durezol(TM) has been accepted by the U.S. Food and Drug Administration (FDA) and granted priority review. Sirion Therapeutics is seeking approval from the FDA for its investigational compound Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a twice-daily steroid, as a treatment for postoperative ocular inflammation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

Priority review is granted by the FDA to those drugs that have the potential to provide a significant improvement compared to marketed products. This designation results in a review period of six months from the date of receipt of the NDA. The FDA has issued an action date of June 26, 2008 under the Prescription Drug User Fee Act (PDUFA).

Data from two Phase 3 clinical studies in post-operative inflammation will be presented at the American Society of Cataract and Refractive Surgery 2008 Symposium and Congress on Tuesday, April 8, 2008 at 8:32 am in room 176B at McCormick Place West in Chicago, IL.

Durezol(TM) is the trademark of Sirion Therapeutics Inc. and is currently under review by the U.S. Food and Drug Administration and has not yet been cleared as the trade name for commercial use.

About Post-Operative Inflammation

Over five million ophthalmic surgeries are performed each year in the United States. Post-operative inflammation is a common occurrence following these procedures, and if left untreated, can interfere with a patient's visual rehabilitation or lead to further complications. While the inflammation tends to be self-resolving, some cases can lead to other serious conditions if left untreated. As there is no way to predict which patients might develop inflammat
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
2. Prime Therapeutics Introduces Efficiency Program to Help Employers Understand How to Most Effectively Spend Pharmacy Dollars
3. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
4. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
5. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
6. Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing
7. Transition Therapeutics Announces Second Quarter Fiscal 2008 Financial Results
8. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
9. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
10. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST
11. Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Dr. Andrew Satlin offers patients with gum disease ... Assisted New Attachment Procedure (LANAP). May is Stroke Awareness Month, ... gum disease and stroke. Periodontal disease is one of the ... is linked to an increased risk for strokes because of ... pockets. , Periodontal disease is essentially an infection of ...
(Date:5/22/2013)... ARLINGTON, VA (PRWEB) May 22, 2013 TWITTER: ... 5th Military Family Tour together, heading to 8 countries in the ... , Sesame Street, Cookie Monster and Members of Congress came together ... nation and assembled 2,000 USO Care Packages for distribution ... hand to celebrate the five-year partnership of Sesame Street and the ...
(Date:5/22/2013)... The Muscular Dystrophy Association scored a huge win ... Charlotte Muscle Team event held May 21 by raising ... muscle disease. , "The Charlotte community really showed ... said MDA Divisional Director Theresa Miller. “From the pro ... to make their night extra special, to the business ...
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) ... knows there is something about feet that fungi seem ... "map" of the fungal groups that live on your ... hottest neighborhood. It,s no secret that the human ... viruses and fungi, both outside and inside. And it,s ...
(Date:5/22/2013)... Grants Pass, OR (PRWEB) May 22, 2013 ... granted, and it is leading to water shortages. In much ... a luxury, according to water advocate, Sharon Kleyne. She warns ... and conserve the water that is available so easily in ... Sharon Kleyne Hour Power of Water radio show, heard live ...
Breaking Medicine News(10 mins):Health News:For Stroke Awareness Month, Dr. Andrew Satlin is Raising Awareness of the Connections Between Gum Disease and Stroke and Offers Encino, CA Laser Gum Surgery for Treatment 2Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 2Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 3Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 4Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 5Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2Health News:Scientists Map the Fungi on Your Feet 2Health News:Scientists Map the Fungi on Your Feet 3Health News:Water Advocate Sharon Kleyne Announces Water Conservation Appreciation 2
... MINNEAPOLIS, Feb. 29 Vallon Holdings, LLC, ... a new professional services subsidiary providing experienced,interim ... science,companies., "Vallon LifeScience is a breakthrough ... science companies today," states Paula J. Norbom, ...
... March for Babies 2008 Official Shoes are Now On Sale, ... has teamed up with Famous Footwear(TM) and Dr. Scholl,s(R) to,introduce ... the third consecutive year, Famous Footwear and Dr. Scholl,s are,raising ... shoe styles.,Dr. Scholl,s specially designed one men,s and two women,s ...
... America (Nasdaq: DCAI ) announced today that it ... results on March 13, 2008, after the,close of the ... conjunction with its quarterly earnings releases, beginning with this,quarter. ... March 14,2008 at 10:00 AM EDT., Those interested ...
... JERSEY, FEBRUARY 29 -- Otsuka Pharmaceutical Co., Ltd. and ... U.S. Food and Drug Administration (FDA) approved the supplemental ... treatment of manic and mixed episodes associated with Bipolar ... patients (10 to 17 years old). ABILIFY has ...
... the Mojave Desert, Calif., has found that soils under desert ... of salt, close to the surface. Vulnerable to erosion by ... vast source of nitrate could contaminate surface and groundwaters, posing ... the March issue of Geology . , Desert pavement ...
... Springer and the Japanese Society of Hematology announce a ... The journal is available (back to 1997) ... appears ten times a year and was previously published ... of Hematology, which is the official journal of the ...
Cached Medicine News:Health News:Vallon Holdings, LLC Launches New Subsidiary Focused on Contract Resources for the Minneapolis-St. Paul Life Science Industry 2Health News:Famous Footwear, Dr. Scholl's Step Up to Support March for Babies 2008 2Health News:Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date 2Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 2Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 3Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 4Health News:Large source of nitrate, a potential water contaminant, found in near-surface desert soils 2Health News:Large source of nitrate, a potential water contaminant, found in near-surface desert soils 3Health News:Springer to publish International Journal of Hematology 2
(Date:5/22/2013)... May 22, 2013  Flagship Ventures, a leading ... healthcare and sustainability, today announced the appointment of ... Senior Partner. In this role, Mr. Bancel will ... In addition to working closely with ... serves as President and Chief Executive Officer of ...
(Date:5/22/2013)... -- Grifols, a global healthcare company based in ... demonstrating that a higher dose of PROLASTIN © -C ... alpha 1 protein in patients with alpha 1 ... the normal range for healthy individuals. AAT deficiency is ... the alpha 1 proteinase inhibitor (A1PI) protein can ...
(Date:5/22/2013)... , May 22, 2013  Ohr Pharmaceutical Inc. ... of novel therapeutics for unmet medical needs, today announced ... , M.D., Ph.D., to its Board of Directors. Dr. ... on early and late stage drug development. ... Ohr,s Board," said Dr. Irach Taraporewala, CEO of Ohr ...
Breaking Medicine Technology:Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 2Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 3
... 15 ITelagen, Inc., innovative provider of healthcare ... Medical Services, Inc., a leading regional distributor of medical supplies, equipment ... today of the final rule on "meaningful use" of an electronic ... , , ...
... July 15 Merz Aesthetics today announced it is now shipping ... only available in Europe , Asclera™ was recently approved by the ... , , ... Phlebology , leading experts conclude that polidocanol is a highly effective ...
Cached Medicine Technology:Bell Medical and ITelagen Welcome Final Rule for 'Meaningful Use' of Electronic Health Records 2Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 2Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 3Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: